Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 9/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059892 | 0.78 | ALDH1A1 (0.50) | CYP2A6SCN9AMAOBTNKS2 | |
| SCHEMBL4212713 | 0.77 | F10 (0.56) | F10 | |
| SCHEMBL3667343 | 0.73 | GRM5 (0.47) | SCN9APAK1MAOB | |
| SCHEMBL10059904 | 0.73 | CYP1A2 (0.38) | CYP2A6SCN9ATNKS2 | |
| SCHEMBL143175 | 0.72 | ALDH1A1 (0.54) | F10 | |
| SCHEMBL2645575 | 0.71 | DDB1 (0.41) | F10 | |
| SCHEMBL142777 | 0.70 | F10 (0.44) | F10 | |
| SCHEMBL2539751 | 0.70 | F10 (0.39) | F10 | |
| SCHEMBL1277801 | 0.70 | FAAH (0.43) | F10 | |
| SCHEMBL92819 | 0.70 | KDM4E (0.57) | F10NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |